Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: rank test returned 17 record(s)
|
|
Monday, 07/30/2018
|
Achieving Optimal Power of Logrank Test with Random Treatment Time-Lag Effect
Zhenzhen Xu , FDA; Yongsoek Park, Unversity of Pittsburgh; Boguang Zhen, FDA; Bin Zhu, NIH/NCI
11:00 AM
|
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Treatment Effect
Boguang Zhen, FDA; Zhenzhen Xu , FDA; Bin Zhu, NIH/NCI; Yongsoek Park, Unversity of Pittsburgh
11:25 AM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:20 PM
|
Considering Delayed Treatment Effect in Trial Designs with Survival Endpoints
Kaushal Mishra, Novartis Oncology Pharmaceuticals; Kalyanee Viraswami Appanna, Novartis Pharmaceuticals
2:20 PM
|
|
Tuesday, 07/31/2018
|
Extended Rank Tests for Analyzing Recurrent Event Data
Qiang Zhao; Mark Chang, Veristat; Michael LaValley, Boston University; Joseph M. Massaro, Boston University; Bin Zhang, Seqirus; Kathryn Lunetta, Boston University
|
Systematic Review of Test/Estimation Approach in Comparative Cancer Clinical Studies with Time-To-Event Outcomes
Miki Horiguchi, Kitasato University; Hajime Uno, Dana Farber Cancer Institute
9:05 AM
|
Extended Rank Tests for Analyzing Recurrent Event Data
Qiang Zhao; Mark Chang, Veristat; Michael LaValley, Boston University; Joseph M. Massaro, Boston University; Bin Zhang, Seqirus; Kathryn Lunetta, Boston University
9:15 AM
|
Design Considerations in Clinical Trials with Cure Rate Survival Data: a Case Study in Oncology
Grace Liu, Johnson & Johnson; Steven Sun, J&J; Tzu-min Yhe, janssen pharmaceuticals; Tianmeng Lyu, University of Minnesota; Rao Sudhakar, janssen pharmaceuticals; Bruce Xue, Johnson & Johnson China
9:20 AM
|
A Graphical Dissection of the Log-Rank Test and Cox Proportional Hazards Model
Xiaofei Hu, Abbvie; Yabing Mai, AbbVie, Inc
10:35 AM
|
Analysis of Stratified Clinical Trials with Time-To-Event Endpoints
Devan V Mehrotra, Merck & Co., Inc.; Shanjun Helian, Merck & Co., Inc.; Shu-Chih Su, Merck Research Labs
3:05 PM
|
Change-Point Analysis Using Logarithmic Quantile Estimation
Lucia Tabacu, Old Dominion University; Mark Ledbetter, Old Dominion University
3:20 PM
|
|
Wednesday, 08/01/2018
|
Moving Beyond Longrank/Hazard Ratio Test/Estimation Approach in Cancer Clinical Trials
Hajime Uno, Dana Farber Cancer Institute; Miki Horiguchi, Kitasato University
8:35 AM
|
Weighted Log-Rank Test for Time-To-Event Data in Immunotherapy Trials with Random Delayed Treatment Effect and Cure Rate
Shufang Liu, Astellas Pharma; Chenghao Chu, Indiana University, Fairbanks School of Public Health; Alan Rong, Data Science, Astellas Pharma Inc.
9:35 AM
|
Improving Testing and Description of Treatment Effect in Clinical Trials with Time-To-Event Outcomes
Song Yang, NHLBI/NIH
11:50 AM
|
Tests for Patterned Alternatives Using Logarithmic Quantile Estimation
Mark Ledbetter, Old Dominion University; Lucia Tabacu, Old Dominion University
3:20 PM
|
|
|
